Innovation for Patients Driven by

The Potential to Forever Change How Cancer is Treated

Allogene Therapeutics is pioneering the development of allogeneic CAR T therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first- generation autologous CAR T therapies to deliver breakthrough clinical benefits, but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.

Learn More

Accelerating an
Expansive Portfolio

We are advancing our allogeneic CAR T cell portfolio acquired from Pfizer, which includes rights to 16 preclinical CAR T cell therapy targets licensed from Cellectis and Servier and U.S. rights to UCART19, an allogeneic CAR T cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. In partnership with Servier, UCART19 is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).

Learn More

Led by a Veteran Team

We were co-founded by a team that includes Dr. Arie Belldegrun and Dr. David Chang, who developed one of the first CAR T cell therapies approved by the U.S. Food and Drug Administration. They have unparalleled scientific, clinical and regulatory expertise, and a track record of success.

Learn More

Latest News

Dec 03
2018

Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia

Learn More >
Dec 03
2018

Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting

Learn More >
Nov 05
2018

Allogene Therapeutics Announces November 2018 Investor Conference Schedule

Learn More >
Nov 01
2018

Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting

Learn More >
Oct 15
2018

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Learn More >
Oct 10
2018

Allogene Therapeutics Announces Pricing of Initial Public Offering

Learn More >
Sep 27
2018

Allogene Therapeutics Appoints Deborah M. Messemer, Former KPMG Managing Partner, to its Board of Directors

Learn More >
Sep 14
2018

Allogene Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering

Learn More >
Sep 06
2018

Allogene Therapeutics Completes a $120 Million Private Financing

Learn More >
Aug 28
2018

Allogene Therapeutics Appoints David M. Tillett, Ph.D., as Senior Vice President, Head of Quality August 14, 2018

Learn More >
Aug 14
2018

Allogene Therapeutics Appoints Susie Jun, M.D., Ph.D., as Chief Development Officer

Learn More >
Jul 10
2018

Allogene Therapeutics Announces Scientific Advisory Board

Learn More >
Jun 18
2018

Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer

Learn More >
Jun 12
2018

Cellectis Publishes Novel Methods to Improve the Clinical Use of Chimeric Antigen Receptor T-Cell Therapy in Scientific Reports

Learn More >
Jun 04
2018

Allogene Therapeutics Appoints Alison Moore, Ph.D. as Chief Technical Officer

Learn More >
May 30
2018

Allogene Therapeutics Announces Board of Directors

Learn More >
May 14
2018

Allogene Therapeutics Announces Poster Presentation at the Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Learn More >
Apr 09
2018

Allogene Therapeutics Completes Agreement for Pfizer’s Allogeneic CAR T Immuno-­oncology Portfolio

Learn More >
Apr 03
2018

Cellectis and Allogene Therapeutics Intend to Continue Strategic Cancer Immunotherapy Collaboration to Accelerate Development and Commercialization of Allogeneic Off-the-Shelf CAR T Therapies

Learn More >
Apr 03
2018

Pfizer and Allogene Therapeutics Enter Into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio

Learn More >